Deutsch  |  English

Southern Germany: the biotechnological center – and more

"Southern Germany, and the region of Ulm and Upper Swabia in particular, have developed into a worldwide center for biotechnology", says Hermann Allgaier, Managing Director of our Biotech plant in Ulm, but we have more to offer. "This is especially true in terms of research, with an excellent academic environment including the universities in Ulm, Stuttgart and Tubingen, as well as the higher education institutions in Biberach and Esslingen and the Fraunhofer Institute, which has developed over the years to become a recognized biological  Center of Competence."

find out more

The new biotech plant in Ulm – a biotechnology landmark!

A high interest domain for biotechnologists, bioprocess technicians, biochemists, scientists and engineers, in other words, experts like you.

If you have been waiting for the opportunity to make your mark in the development and operation of a brand new plant for manufacturing recombinant proteins from animal cell cultures, then you have come to the right place at Teva, one of the 10 largest pharmaceutical companies worldwide and its three-digit million investment in this plant.

find out more

With us as your employer: grow with the best!

We are  Teva Pharmaceutical Industries, a worldwide leading company with the objective of providing patients with top quality patient-oriented health solutions day in, day out. We are now expanding our biotechnological competence on the basis of our state of the art production facility in Ulm, inaugurated in 2006 and its highly successful track record.

find out more

The new Ulm biotech plant – Teva in Ulm!

You won’t find a healthy, medium-sized structure backed by a true global player with 43,000 employees every day – well, here you do:

In the field of manufacturing biosimilars, which may be of specific interest to you, we have managed to position ourselves as a top performer within the Group. Around the world, we have earned confidence that the considerable investment for building the new biotech plant here in southern Germany is in the right hands and that we will do an excellent job.

find out more

With its new biotechnological production plant, Teva will be in a position to manufacture monoclonal antibodies for a broad range of indications at the site in Ulm. Monoclonal antibodies represent the largest growth market in biopharmaceuticals. "Whereas, whether we are talking about innovative substances or biotechnologically manufactured generics, the so-called biosimilars, is irrelevant. We can, and will, manufacture both", Dr. Allgaier, Managing Director Biotech emphasizes.

News

Find out more about the current progress of our Teva Biotech site in Ulm here.

read more

Choose a market leader, take on responsibility and create your everyday environment, your future and ours, and that of thousands of patients worldwide! Be a part of change and work in an open, constructive atmosphere in our new biotech plant in the Ulm biotechnology center. We look forward to meeting you.

Current job vacancies can be found on our careers page.